Home Alzheimer’s Disease Trastuzumab Deruxtecan Shows Promise in HER2 Targeted Therapy

Trastuzumab Deruxtecan Shows Promise in HER2 Targeted Therapy

The antibody-drug conjugate trastuzumab deruxtecan (T-DXd) showed promising activity in multiple non-breast/non-gastric cancer types with heavily pretreated HER2-expressing or HER2-mutant solid tumors, according to a recent study published in Cancer Discovery.1

More specifically, the T-DXd combination showed even greater antitumor activity in patients with HER2-mutant non-small cell lung cancer (NSCLC).

“HER2-targeted therapies have proven successful for patients with breast and gastric cancers; however, there are no approved HER2-targeted therapies available for patients with other HER2-overexpressing or HER2-mutated malignancies,” Bob Li, MD, senior author on the study said in a press release. 2 “Conventional therapies for these other HER2-overexpressing cancers tend to have limited efficacy and considerable side effects. Additional treatment options are urgently needed for…

Continue Reading to the Source

LEAVE A REPLY

Please enter your comment!
Please enter your name here

Most Popular

Parasite found in undercooked meat linked with risk of rare brain cancer

submitted by /u/Meat_Mithkabob Continue Reading to the Source

Living up to expectations : braincancer

Hey everyone!I wrote a little something about some of the comments you often hear from others and how sometimes you feel like you need...

My Brain Tumor Taught Me To Shift My Perspective on These 5 Things

submitted by /u/andrewjoegeorge Continue Reading to the Source

Recent Comments